LAPTM4B counteracts ferroptosis via suppressing the ubiquitin-proteasome degradation of SLC7A11 in non-small cell lung cancer

Ruyu Yan,Dan Liu,Hongjuan Guo,Minxia Liu,Dongjin Lv,Benny Björkblom,Mingsong Wu,Hongtao Yu,Hao Leng,Bingxiao Lu,Yuxiang Li,Miaomiao Gao,Tomas Blom,Kecheng Zhou
DOI: https://doi.org/10.1038/s41419-024-06836-x
2024-06-21
Cell Death and Disease
Abstract:Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths worldwide, necessitating the identification of novel therapeutic targets. Lysosome Associated Protein Transmembrane 4B (LAPTM4B) is involved in biological processes critical to cancer progression, such as regulation of solute carrier transporter proteins and metabolic pathways, including mTORC1. However, the metabolic processes governed by LAPTM4B and its role in oncogenesis remain unknown. In this study, we conducted unbiased metabolomic screens to uncover the metabolic landscape regulated by LAPTM4B. We observed common metabolic changes in several knockout cell models suggesting of a role for LAPTM4B in suppressing ferroptosis. Through a series of cell-based assays and animal experiments, we demonstrate that LAPTM4B protects tumor cells from erastin-induced ferroptosis both in vitro and in vivo. Mechanistically, LAPTM4B suppresses ferroptosis by inhibiting NEDD4L/ZRANB1 mediated ubiquitination and subsequent proteasomal degradation of the cystine-glutamate antiporter SLC7A11. Furthermore, metabolomic profiling of cancer cells revealed that LAPTM4B knockout leads to a significant enrichment of ferroptosis and associated metabolic alterations. By integrating results from cellular assays, patient tissue samples, an animal model, and cancer databases, this study highlights the clinical relevance of the LAPTM4B-SLC7A11-ferroptosis signaling axis in NSCLC progression and identifies it as a potential target for the development of cancer therapeutics.
cell biology
What problem does this paper attempt to address?
The paper aims to study the metabolic regulatory role of the LAPTM4B protein in non-small cell lung cancer (NSCLC) and its relationship with ferroptosis. The main issues addressed include: 1. **Metabolic Regulation**: Through unbiased metabolomics screening, the metabolic landscape regulated by LAPTM4B is revealed, particularly its mechanism in inhibiting ferroptosis. 2. **Ferroptosis Inhibition Mechanism**: The study found that LAPTM4B inhibits ferroptosis by preventing the ubiquitin-proteasome degradation of the SLC7A11 protein. Specifically, LAPTM4B achieves this by inhibiting the NEDD4L/ZRANB1-mediated ubiquitination of SLC7A11. 3. **Clinical Significance**: The paper also explores the clinical relevance of the LAPTM4B-SLC7A11-ferroptosis signaling axis in the progression of NSCLC, suggesting that this signaling pathway could be a potential target for developing cancer therapeutics. These findings provide new insights into the role of LAPTM4B in NSCLC and lay the foundation for its potential as a therapeutic target.